These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19903812)

  • 41. Outer domain of HIV-1 gp120: antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04.
    Joyce MG; Kanekiyo M; Xu L; Biertümpfel C; Boyington JC; Moquin S; Shi W; Wu X; Yang Y; Yang ZY; Zhang B; Zheng A; Zhou T; Zhu J; Mascola JR; Kwong PD; Nabel GJ
    J Virol; 2013 Feb; 87(4):2294-306. PubMed ID: 23236069
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies.
    Kwong PD; Mascola JR
    Immunity; 2012 Sep; 37(3):412-25. PubMed ID: 22999947
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12.
    Huskens D; Van Laethem K; Vermeire K; Balzarini J; Schols D
    Virology; 2007 Apr; 360(2):294-304. PubMed ID: 17123566
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12.
    Sterjovski J; Churchill MJ; Ellett A; Wesselingh SL; Ramsland PA; Gorry PR
    Virology; 2012 Oct; 432(2):394-404. PubMed ID: 22818780
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Structural Constraints at the Trimer Apex Stabilize the HIV-1 Envelope in a Closed, Antibody-Protected Conformation.
    Guzzo C; Zhang P; Liu Q; Kwon AL; Uddin F; Wells AI; Schmeisser H; Cimbro R; Huang J; Doria-Rose N; Schmidt SD; Dolan MA; Connors M; Mascola JR; Lusso P
    mBio; 2018 Dec; 9(6):. PubMed ID: 30538178
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
    Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
    J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
    Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
    J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.
    Chakrabarti BK; Pancera M; Phogat S; O'Dell S; McKee K; Guenaga J; Robinson J; Mascola J; Wyatt RT
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):877-87. PubMed ID: 21158699
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.
    Ingale J; Tran K; Kong L; Dey B; McKee K; Schief W; Kwong PD; Mascola JR; Wyatt RT
    J Virol; 2014 Dec; 88(24):14002-16. PubMed ID: 25253346
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Structural analysis of human and macaque mAbs 2909 and 2.5B: implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120.
    Spurrier B; Sampson JM; Totrov M; Li H; O'Neal T; Williams C; Robinson J; Gorny MK; Zolla-Pazner S; Kong XP
    Structure; 2011 May; 19(5):691-9. PubMed ID: 21565703
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F.
    Revilla A; Delgado E; Christian EC; Dalrymple J; Vega Y; Carrera C; González-Galeano M; Ocampo A; de Castro RO; Lezaún MJ; Rodríguez R; Mariño A; Ordóñez P; Cilla G; Cisterna R; Santamaría JM; Prieto S; Rakhmanova A; Vinogradova A; Ríos M; Pérez-Álvarez L; Nájera R; Montefiori DC; Seaman MS; Thomson MM
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):889-901. PubMed ID: 21226626
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational method.
    Evans MC; Phung P; Paquet AC; Parikh A; Petropoulos CJ; Wrin T; Haddad M
    BMC Bioinformatics; 2014 Mar; 15():77. PubMed ID: 24646213
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness.
    Pietzsch J; Scheid JF; Mouquet H; Klein F; Seaman MS; Jankovic M; Corti D; Lanzavecchia A; Nussenzweig MC
    J Exp Med; 2010 Aug; 207(9):1995-2002. PubMed ID: 20679402
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1.
    Yang X; Tomov V; Kurteva S; Wang L; Ren X; Gorny MK; Zolla-Pazner S; Sodroski J
    J Virol; 2004 Dec; 78(23):12975-86. PubMed ID: 15542649
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glycan Microheterogeneity at the PGT135 Antibody Recognition Site on HIV-1 gp120 Reveals a Molecular Mechanism for Neutralization Resistance.
    Pritchard LK; Spencer DI; Royle L; Vasiljevic S; Krumm SA; Doores KJ; Crispin M
    J Virol; 2015 Jul; 89(13):6952-9. PubMed ID: 25878100
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies.
    Doria-Rose NA; Georgiev I; O'Dell S; Chuang GY; Staupe RP; McLellan JS; Gorman J; Pancera M; Bonsignori M; Haynes BF; Burton DR; Koff WC; Kwong PD; Mascola JR
    J Virol; 2012 Aug; 86(15):8319-23. PubMed ID: 22623764
    [TBL] [Abstract][Full Text] [Related]  

  • 57. AIDS/HIV. A boost for HIV vaccine design.
    Burton DR; Weiss RA
    Science; 2010 Aug; 329(5993):770-3. PubMed ID: 20705840
    [No Abstract]   [Full Text] [Related]  

  • 58. A single residue within the V5 region of HIV-1 envelope facilitates viral escape from the broadly neutralizing monoclonal antibody VRC01.
    Guo D; Shi X; Arledge KC; Song D; Jiang L; Fu L; Gong X; Zhang S; Wang X; Zhang L
    J Biol Chem; 2012 Dec; 287(51):43170-9. PubMed ID: 23100255
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterization of the multiple conformational States of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker.
    Yuan W; Bazick J; Sodroski J
    J Virol; 2006 Jul; 80(14):6725-37. PubMed ID: 16809278
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120.
    Doran RC; Morales JF; To B; Morin TJ; Theolis R; O'Rourke SM; Yu B; Mesa KA; Berman PW
    Mol Immunol; 2014 Nov; 62(1):219-226. PubMed ID: 25016576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.